Iron overload in FRDA PBMCs limited by artesunate supplementation. (A) Iron content (at 8-hour intervals), determined by ferrozine-based colorimetric assay, of PBMCs from healthy donors (C4-C7), heterozygous carriers of FXN GAA expansions (carriers 1-3), and FRDA patients (P1, P6-P14) grown in high-iron medium (100 µM of FAC) for 40 hours (n = 1). (B) Iron content of PBMCs from controls (C8-9), heterozygous carriers of FXN GAA expansions (carriers 4-5), and FRDA patients with compound heterozygous FXN GAA expansions (P15-16) grown for 40 hours in high-iron medium (100 µM of FAC), with or without 25 µM artesunate (n = 1).